TY  - GEN
AU  - Davies,Melanie J
AU  - Leiter,Lawrence A
AU  - Guerci,Bruno
AU  - Grunberger,George
AU  - Ampudia-Blasco,F Javier
AU  - Yu,Christine
AU  - Stager,William
AU  - Niemoeller,Elisabeth
AU  - Souhami,Elisabeth
AU  - Rosenstock,Julio
TI  - Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents
SN  - 1463-1326
PY  - 2018///0720
KW  - Body Mass Index
KW  - Diabetes Mellitus, Type 2
KW  - complications
KW  - Disease Progression
KW  - Drug Combinations
KW  - Drug Resistance
KW  - Drug Therapy, Combination
KW  - adverse effects
KW  - Glucagon-Like Peptide-1 Receptor
KW  - metabolism
KW  - Glycated Hemoglobin
KW  - analysis
KW  - Humans
KW  - Hyperglycemia
KW  - prevention & control
KW  - Hypoglycemia
KW  - chemically induced
KW  - Insulin Glargine
KW  - administration & dosage
KW  - Middle Aged
KW  - Obesity
KW  - Peptides
KW  - Postprandial Period
KW  - Weight Gain
KW  - drug effects
KW  - Glucagon-Like Peptide-1 Receptor Agonists
N1  - Publication Type: Comparative Study; Equivalence Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1111/dom.12980
ER  -